Cellular immunotherapy study of prostate cancer patients and resulting IgG responses to peptide epitopes predicted from prostate tumor-associated autoantigens

George P. Hemstreet, Gabriela R. Rossi, Vladimir M. Pisarev, Charles Arthur Enke, Laura Helfner, Ralph J. Hauke, Lucinda Tennant, William Jay Ramsey, Nicholas N. Vahanian, Charles J. Link

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The immunogenicity of a cellular immunotherapy using genetically modified vaccines to express α(1,3)galactosyl epitopes (αGal) was evaluated in advanced prostate cancer (PC) patients. In this dose escalation phase I study, we report safety, feasibility, and immunologic data of an immunotherapy composed of 2 human PC cell lines engineered to express αGal epitopes (HyperAcute-Prostate, HAP, NewLink Genetics). Eight patients received up to 12 biweekly vaccinations with HAP. Enrolled patients (aged range, 53-85 y) had American Joint Committee on Cancer stage IV, any T, any N, M1, Eastern Cooperative Oncology Group PS≤2, at least 1 prior hormonal treatment and <3 prior chemotherapies, adequate bone marrow and organ function, and albumin ?3.0 g/dL. Serum IgG antibodies to synthetic peptides overexpressed in PC were determined by enzyme-linked immunosorbent assay. Results indicate that HAP immunotherapy induced humoral immune responses to autoantigens in 2 of 8 patients. These patients developed IgG antibody to multiple epitopes overexpressed in PC after immunization. These responding patients received higher doses of the immunotherapy suggesting a dose response. Two immunogenic proteins (prostate-specific membrane antigen, hepsin) belong to the extracellular molecules family participating in malignant cell invasion. Median overall survival for patients was 25.1 months with 1 patient surviving over 70 months with stable PSA and bone metastasis before expiring of other causes. Three of 8 patients showed PSA stabilization (>100 d). In conclusion, HAP immunotherapy induces IgG responses to epitopes from autoantigens overexpressed in PC suggesting dose-dependent effect. HAP represents a viable immunotherapy approach to induce immune responses against tumor cells and may provide clinical benefit with minimal toxicity.

Original languageEnglish (US)
Pages (from-to)57-65
Number of pages9
JournalJournal of Immunotherapy
Volume36
Issue number1
DOIs
StatePublished - Jan 1 2013

Fingerprint

Autoantigens
Immunotherapy
Prostate
Epitopes
Prostatic Neoplasms
Immunoglobulin G
Peptides
Neoplasms
Vaccination
Vaccines
Safety
Cell Line
Therapeutics

Keywords

  • a(1,3)Galactosyl epitope
  • hyperacute rejection
  • prostate cancer
  • tumor-derived peptide

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Cite this

Cellular immunotherapy study of prostate cancer patients and resulting IgG responses to peptide epitopes predicted from prostate tumor-associated autoantigens. / Hemstreet, George P.; Rossi, Gabriela R.; Pisarev, Vladimir M.; Enke, Charles Arthur; Helfner, Laura; Hauke, Ralph J.; Tennant, Lucinda; Ramsey, William Jay; Vahanian, Nicholas N.; Link, Charles J.

In: Journal of Immunotherapy, Vol. 36, No. 1, 01.01.2013, p. 57-65.

Research output: Contribution to journalArticle

Hemstreet, George P. ; Rossi, Gabriela R. ; Pisarev, Vladimir M. ; Enke, Charles Arthur ; Helfner, Laura ; Hauke, Ralph J. ; Tennant, Lucinda ; Ramsey, William Jay ; Vahanian, Nicholas N. ; Link, Charles J. / Cellular immunotherapy study of prostate cancer patients and resulting IgG responses to peptide epitopes predicted from prostate tumor-associated autoantigens. In: Journal of Immunotherapy. 2013 ; Vol. 36, No. 1. pp. 57-65.
@article{ac239293bebd406ba3db0f3bca22ad87,
title = "Cellular immunotherapy study of prostate cancer patients and resulting IgG responses to peptide epitopes predicted from prostate tumor-associated autoantigens",
abstract = "The immunogenicity of a cellular immunotherapy using genetically modified vaccines to express α(1,3)galactosyl epitopes (αGal) was evaluated in advanced prostate cancer (PC) patients. In this dose escalation phase I study, we report safety, feasibility, and immunologic data of an immunotherapy composed of 2 human PC cell lines engineered to express αGal epitopes (HyperAcute-Prostate, HAP, NewLink Genetics). Eight patients received up to 12 biweekly vaccinations with HAP. Enrolled patients (aged range, 53-85 y) had American Joint Committee on Cancer stage IV, any T, any N, M1, Eastern Cooperative Oncology Group PS≤2, at least 1 prior hormonal treatment and <3 prior chemotherapies, adequate bone marrow and organ function, and albumin ?3.0 g/dL. Serum IgG antibodies to synthetic peptides overexpressed in PC were determined by enzyme-linked immunosorbent assay. Results indicate that HAP immunotherapy induced humoral immune responses to autoantigens in 2 of 8 patients. These patients developed IgG antibody to multiple epitopes overexpressed in PC after immunization. These responding patients received higher doses of the immunotherapy suggesting a dose response. Two immunogenic proteins (prostate-specific membrane antigen, hepsin) belong to the extracellular molecules family participating in malignant cell invasion. Median overall survival for patients was 25.1 months with 1 patient surviving over 70 months with stable PSA and bone metastasis before expiring of other causes. Three of 8 patients showed PSA stabilization (>100 d). In conclusion, HAP immunotherapy induces IgG responses to epitopes from autoantigens overexpressed in PC suggesting dose-dependent effect. HAP represents a viable immunotherapy approach to induce immune responses against tumor cells and may provide clinical benefit with minimal toxicity.",
keywords = "a(1,3)Galactosyl epitope, hyperacute rejection, prostate cancer, tumor-derived peptide",
author = "Hemstreet, {George P.} and Rossi, {Gabriela R.} and Pisarev, {Vladimir M.} and Enke, {Charles Arthur} and Laura Helfner and Hauke, {Ralph J.} and Lucinda Tennant and Ramsey, {William Jay} and Vahanian, {Nicholas N.} and Link, {Charles J.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1097/CJI.0b013e3182780abc",
language = "English (US)",
volume = "36",
pages = "57--65",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Cellular immunotherapy study of prostate cancer patients and resulting IgG responses to peptide epitopes predicted from prostate tumor-associated autoantigens

AU - Hemstreet, George P.

AU - Rossi, Gabriela R.

AU - Pisarev, Vladimir M.

AU - Enke, Charles Arthur

AU - Helfner, Laura

AU - Hauke, Ralph J.

AU - Tennant, Lucinda

AU - Ramsey, William Jay

AU - Vahanian, Nicholas N.

AU - Link, Charles J.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - The immunogenicity of a cellular immunotherapy using genetically modified vaccines to express α(1,3)galactosyl epitopes (αGal) was evaluated in advanced prostate cancer (PC) patients. In this dose escalation phase I study, we report safety, feasibility, and immunologic data of an immunotherapy composed of 2 human PC cell lines engineered to express αGal epitopes (HyperAcute-Prostate, HAP, NewLink Genetics). Eight patients received up to 12 biweekly vaccinations with HAP. Enrolled patients (aged range, 53-85 y) had American Joint Committee on Cancer stage IV, any T, any N, M1, Eastern Cooperative Oncology Group PS≤2, at least 1 prior hormonal treatment and <3 prior chemotherapies, adequate bone marrow and organ function, and albumin ?3.0 g/dL. Serum IgG antibodies to synthetic peptides overexpressed in PC were determined by enzyme-linked immunosorbent assay. Results indicate that HAP immunotherapy induced humoral immune responses to autoantigens in 2 of 8 patients. These patients developed IgG antibody to multiple epitopes overexpressed in PC after immunization. These responding patients received higher doses of the immunotherapy suggesting a dose response. Two immunogenic proteins (prostate-specific membrane antigen, hepsin) belong to the extracellular molecules family participating in malignant cell invasion. Median overall survival for patients was 25.1 months with 1 patient surviving over 70 months with stable PSA and bone metastasis before expiring of other causes. Three of 8 patients showed PSA stabilization (>100 d). In conclusion, HAP immunotherapy induces IgG responses to epitopes from autoantigens overexpressed in PC suggesting dose-dependent effect. HAP represents a viable immunotherapy approach to induce immune responses against tumor cells and may provide clinical benefit with minimal toxicity.

AB - The immunogenicity of a cellular immunotherapy using genetically modified vaccines to express α(1,3)galactosyl epitopes (αGal) was evaluated in advanced prostate cancer (PC) patients. In this dose escalation phase I study, we report safety, feasibility, and immunologic data of an immunotherapy composed of 2 human PC cell lines engineered to express αGal epitopes (HyperAcute-Prostate, HAP, NewLink Genetics). Eight patients received up to 12 biweekly vaccinations with HAP. Enrolled patients (aged range, 53-85 y) had American Joint Committee on Cancer stage IV, any T, any N, M1, Eastern Cooperative Oncology Group PS≤2, at least 1 prior hormonal treatment and <3 prior chemotherapies, adequate bone marrow and organ function, and albumin ?3.0 g/dL. Serum IgG antibodies to synthetic peptides overexpressed in PC were determined by enzyme-linked immunosorbent assay. Results indicate that HAP immunotherapy induced humoral immune responses to autoantigens in 2 of 8 patients. These patients developed IgG antibody to multiple epitopes overexpressed in PC after immunization. These responding patients received higher doses of the immunotherapy suggesting a dose response. Two immunogenic proteins (prostate-specific membrane antigen, hepsin) belong to the extracellular molecules family participating in malignant cell invasion. Median overall survival for patients was 25.1 months with 1 patient surviving over 70 months with stable PSA and bone metastasis before expiring of other causes. Three of 8 patients showed PSA stabilization (>100 d). In conclusion, HAP immunotherapy induces IgG responses to epitopes from autoantigens overexpressed in PC suggesting dose-dependent effect. HAP represents a viable immunotherapy approach to induce immune responses against tumor cells and may provide clinical benefit with minimal toxicity.

KW - a(1,3)Galactosyl epitope

KW - hyperacute rejection

KW - prostate cancer

KW - tumor-derived peptide

UR - http://www.scopus.com/inward/record.url?scp=84871928430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871928430&partnerID=8YFLogxK

U2 - 10.1097/CJI.0b013e3182780abc

DO - 10.1097/CJI.0b013e3182780abc

M3 - Article

VL - 36

SP - 57

EP - 65

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 1

ER -